Antibodies to TIGIT

US11008390B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Mark F. Maurer · Seattle, US
• Tseng-hui Timothy Chen · Burlingame, US
• Brigitte Devaux · Palo Alto, US
• Mohan Srinivasan · Cupertino, US
• Susan H. Julien · Seattle, US
• Paul O. Sheppard · Granite Falls, US
• Daniel F. ARDOUREL · Woodinville, US
• Indrani Chakraborty · Fremont, US

Key dates

• Filing date: Dec 20, 2018
• Grant date: May 18, 2021
• Expiry date: Jun 16, 2039

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.